Evidence map›Paper›PMID 37822001›Full record

ArticleEuropean journal of medical research2023

Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.

Yi-Xin Zhou, Qian-Cheng Hu, Ya-Juan Zhu, Xiao-Li Mu, Ji-Yan Liu, Ye Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yi-Xin Zhou *Department of Biotherapy, Cancer Centre, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan, China.
Qian-Cheng Hu *Gastric Cancer Center, Division of Medical Oncology, Cancer Center, Laboratory of Gastric Cancer, West China Hospital, Sichuan University, Chengdu, China.
Ya-Juan ZhuDepartment of Biotherapy, Cancer Centre, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan, China.
Xiao-Li MuDepartment of Biotherapy, Cancer Centre, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan, China.
Ji-Yan LiuDepartment of Biotherapy, Cancer Centre, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan, China. liujiyan1972@163.com.ORCID http://orcid.org/0000-0003-4885-5481
Ye ChenDivision of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan, China. huaxichenye@163.com.ORCID http://orcid.org/0000-0001-5317-4846
Sichuan University · CN

Funding

General Program of Sichuan Natural Science Foundation 2022NSFSC0846
6 · The paper itself

Abstract

backgroundTrimodality therapy (TMT) is a mature alternative to radical cystectomy (RC) for patients with muscle-invasive bladder cancer (MIBC) who seek to preserve their primary bladder or are inoperable due to comorbidities. To date, there has been increasing evidence of the effectiveness of TMT as an alternative to RC. In contrast, no literature has stated the effectiveness of neoadjuvant chemotherapy combined with RC (NAC + RC) compared with TMT.

objectiveWe aimed to compare the prognosis between patients receiving TMT and NAC + RC.

methodsThe clinicopathological characteristics of patients with T2-4aN0M0 MIBC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox proportional hazards regression models and Kaplan‒Meier survival curves were used for the survival analysis. Propensity-score matching (PSM) was applied to determine the differences between the two groups. The primary outcome was cancer-specific survival (CSS), and the secondary outcome was overall survival (OS).

resultsIn total, 1,175 patients with MIBC who underwent TMT (n = 822) or NAC + RC (n = 353) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. After 1:1 PSM, the final patient sample included 303 pairs. The prognosis of patients receiving NAC + RC was significantly better than that of patients receiving TMT in both unmatched and matched cohorts (5-year CSS: before PSM, 75.4% vs. 50.6%, P < 0.0001; after PSM, 76.3% vs. 49.5%, P < 0.0001; 5-year OS: before PSM, 71.7% vs. 37.4%, P < 0.0001; after PSM, 71.7% vs. 31.4%, P < 0.0001). The survival advantages of NAC + RC remained remarkable in the stratified analysis of most factors after PSM. Multivariate Cox regression analysis showed that being older than 68 years old, unmarried, grade III/IV, T3-4a stage, and undergoing TMT independently correlated with poor OS.

conclusionThus, in this study, patients with MIBC receiving NAC + RC presented with a better prognosis than those receiving TMT.

Indexed as

Urinary BladderUrinary Bladder NeoplasmsAgedCystectomyHumansMusclesNeoadjuvant TherapyNeoplasm InvasivenessRetrospective StudiesMuscle-invasive bladder cancerNeoadjuvant chemotherapyRadical cystectomyTrimodality therapy

Identifiers

PMID37822001
PMCPMC10566126
OpenAlexW4387533873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.